CONGENITAL ADRENAL HYPERPLASIA
Clinical trials for CONGENITAL ADRENAL HYPERPLASIA explained in plain language.
Never miss a new study
Get alerted when new CONGENITAL ADRENAL HYPERPLASIA trials appear
Sign up with your email to follow new studies for CONGENITAL ADRENAL HYPERPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug trial aims to better control rare hormone disorder in kids
Disease control TerminatedThis study tested a drug called tildacerfont in children aged 2 to 17 with congenital adrenal hyperplasia (CAH), a rare genetic hormone condition. The goal was to see if the drug was safe and if it could help control the disease, potentially allowing for lower doses of standard s…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Experimental drug aims to cut dangerous steroid doses for rare hormone disorder
Disease control TerminatedThis study tested whether a drug called Tildacerfont could safely reduce the high doses of steroid medications that adults with classic congenital adrenal hyperplasia (CAH) need to take. About 100 participants were randomly assigned to receive either the study drug or a placebo f…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2 • Sponsor: Spruce Biosciences • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Early halted trial explores new way to treat rare childhood hormone disorder
Disease control TerminatedThis early-stage study tested whether adding a medication called abiraterone acetate to standard treatment could help young children with a rare inherited hormone disorder (congenital adrenal hyperplasia) safely reduce their daily steroid dose. The goal was to find the lowest eff…
Matched conditions: CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC